Psych Capital Plc Logo

Psych Capital Plc

A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.

PSY | IL

Overview

Corporate Details

ISIN(s):
GB00BL6CJQ54
LEI:
213800WXCQ1C6GPLHH68
Country:
United Kingdom
Address:
17 HANOVER SQUARE, W1S 1BN LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shortwave Life Sciences Plc, formerly Psych Capital Plc, is a life sciences company focused on developing innovative treatments for mental health conditions. The company has transitioned from its prior role as an investment and media firm to a dedicated drug development entity following its acquisition of Short Wave Pharma. Its primary clinical program focuses on advancing psilocybin as a potential breakthrough therapy for anorexia nervosa, a condition with no FDA-approved medication. Rooted in the Israeli innovation ecosystem, Shortwave employs an IP-driven, capital-efficient strategy, utilizing strategic partnerships to optimize its drug discovery and development processes for eating disorders and other mental health indications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 08:00
Board/Management Information
Direction, Director Changes and Medical Adviser
English 20.9 KB
2025-08-19 13:50
Major Shareholding Notification
Holding(s) in Company
English 56.0 KB
2025-08-04 12:00
Board/Management Information
Clarification on Strategic Advisor Appointment
English 6.0 KB
2025-07-29 08:00
Share Issue/Capital Change
£250k Fundraising, New Directors & Review
English 27.3 KB
2025-06-24 14:10
Major Shareholding Notification
AQSE Only - Holding(s) in Company
English 56.2 KB
2025-06-16 11:21
Major Shareholding Notification
Holding(s) in Company
English 56.2 KB
2025-01-31 17:52
Earnings Release
Interim Results to 31 October 2024
English 115.6 KB
2024-12-23 13:00
Share Issue/Capital Change
Pre-Crowdfunding re Groundbreaking Treatment
English 9.5 KB
2024-11-29 16:16
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 7.2 KB
2024-11-27 15:12
Board/Management Information
Director Appointment and SPA Update
English 26.7 KB
2024-10-31 18:39
Annual Report
YEAR ENDED 30 APRIL 2024 AND DIRECTOR RESIGNATION
English 176.8 KB
2024-09-19 08:00
Regulatory News Service
Positive Pre-Clinical Result Drive to Human Trials
English 10.7 KB
2024-07-31 13:05
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 7.2 KB
2024-07-17 18:20
Major Shareholding Notification
TR1: Notification of Major Holdings
English 75.8 KB
2024-07-08 08:00
Share Issue/Capital Change
Company’s Patent Claims Confirmed
English 31.5 KB

Automate Your Workflow. Get a real-time feed of all Psych Capital Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Psych Capital Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.